Effect of yifei jianpi recipe on inflammatory cells, levels of interleukin-8 and tumor necrosis factor-alpha in sputum from patients with chronic obstructive pulmonary disease.
- Author:
Sheng WANG
1
;
Hong-yan JI
;
Nian-zhi ZHANG
;
Xiu-zhen ZHUO
;
Li-ping ZHAO
;
Hui-zhi ZHU
;
Wei CHEN
;
Wei REN
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Aged; Drugs, Chinese Herbal; therapeutic use; Female; Humans; Interleukin-8; metabolism; Leukocyte Count; Male; Middle Aged; Neutrophils; pathology; Phytotherapy; Pulmonary Disease, Chronic Obstructive; drug therapy; metabolism; pathology; Respiratory Function Tests; Sputum; cytology; metabolism; Tumor Necrosis Factor-alpha; metabolism
- From: Chinese Journal of Integrated Traditional and Western Medicine 2005;25(2):111-113
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the effect and the mechanism of yifei jianpi recipe (YFJPR) on patients with chronic obstructive pulmonary disease (COPD).
METHODSForty patients with COPD in stable phase were randomly divided into two groups, the treated group and the control group. Indexes including the total and differential count of inflammatory cell in sputum, levels of interleukin-8 (IL-8) and tumor necrosis factor-alpha (TNF-alpha), as well as the percentage of forced expiratory volume in one second in its predicted value (FEV1%) and ratio of FEV1/forced vital capacity (FVC) in patients were measured before and after treatment, and compared with those in 20 healthy subjects.
RESULTSAll the indexes measured in patients before and after treatment were significantly different from those in healthy subjects (P < 0.01). Differential count of polymorphonuclear neutrophil (PMN) and levels of IL-8 and TNF-alpha in sputum in the treated group significantly decreased after treatment (P < 0.01), while the non-PMN differential count and levels of FEV1% and FEV1/FVC significantly increased (P < 0.01). But in the control group, changes only showed in increasing of FEV1% and FEV1/FVC (P < 0.05 or P < 0.01). And the effects in the treated group were better than those in the control group (P < 0.01).
CONCLUSIONYFJPR can play a therapeutic role on patients with COPD by way of reducing the airway inflammatory reaction.
